In agreement with our results, SF3B2 conferred an aggressive phenotype in prostate cancer and was associated with poor overall survival and progression-free survival in many cancers, such as bladder, lung, and breast cancers [15]. This evidence concerns the gene SF3B2 and prostate carcinoma.